FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life
This study is currently Recruiting
July 2011 By M.D. Anderson Cancer Center
First Recieved on October 30, 2006
Last Updated on July 27, 2011
The primary objectives of this study are:
1. To assess the preferences of cancer patients scheduled to receive chemoradiation and
caregiver controls for side-effects of chemoradiation.
1. To compare preferences of cancer patients to those of healthy individuals.
2. To compare how patients' preferences for side-effects of chemoradiation change
2. To longitudinally assess the quality of life of cancer patients scheduled to receive
3. To determine the impact of nausea and vomiting associated with chemoradiation on
patients' quality of life and evaluate potential change throughout the duration of
||Observational Model: Case Control, Time Perspective: Prospective
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
Patients receiving chemoradiation for abdominal-pelvic tumors.
Healthy controls with no prior cancer diagnosis.
Interview regarding perceptions of side effects that are related to chemoradiation treatment.
3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
|Ages Eligible for Study:||18 Years|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||Accepts Healthy Volunteers|
1. Patients receiving 5 to 6-week course of chemoradiation for abdominal-pelvic tumors
(gastric cancers, gastro-esophageal (GE) junction, pancreatic, cervix, vulvar,
endometrial, or anal) using conventional fractionation [(180cGy-200cGy per day)]
2. Patients receiving concurrent abdominal-pelvic radiation and single agent or
combination of cisplatin, paclitaxel, CPT-11, oxaliplatin or 5-FU, capecitabine,
gemcitabine, or bevacizumab (Avastin).
3. Patients must be least 18 years of age
4. Controls must be individuals with no prior cancer diagnosis
5. Controls must be at least 18 years of age
6. Controls must be the caregivers of patients on this study
1. Patients who do not have a diagnosis of cervix, endometrial, vulvar or anal cancer
2. Patients who are not scheduled to receive chemoradiation treatment
3. Patients who are not at least 18 years of age
4. Controls - individuals who have a prior diagnosis of cancer (with the exception of
non-melanoma skin cancer)
5. Controls - individuals who are not at least 18 years of age
- Investigator: Charlotte C. Sun, MD - Principal Investigator - M.D. Anderson Cancer Center